Quantcast

DrugRisk Adds Pradaxa Warning for Blood Platelet Disorder

May 9, 2013

The DrugRisk Resource Center is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

Chicago, IL (PRWEB) May 09, 2013

The prescription drug resource center DrugRisk.com is alerting patients taking the blood thinner Pradaxa of updated safety information on the site. The warning label for the drug was recently changed to advise that some people using the medication have reported a blood condition*.

The goal of DrugRisk is to improve patient safety by sharing the latest warnings, recalls, studies and legal news related to prescription drugs. Visitors can see if others are experiencing similar side effects and if legal action is under way.

Pradaxa was launched in 2010 to prevent strokes in patients with atrial fibrillation. Experts have disagreed over whether it presents dangerous risks for internal bleeding. The FDA recently advised that Pradaxa is no more dangerous than traditional blood thinner warfarin**.

However, DrugRisk contains information from the Institute for Safe Medication Practices, who warned that patients suffering Pradaxa bleeding are nearly 5 times as likely to die than those with bleeding from Coumadin or warfarin. They also named anticoagulants like Pradaxa among the most dangerous drugs available***.

The resource center also contains a study from the University of Illinois at Chicago suggesting the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than expected****.

Now, DrugRisk is reporting a new Pradaxa side effect warning. Boehringer Ingelheim, the drug maker, recently updated the label to advise that patients using Pradaxa have reported thrombocytopenia, a condition causing a drop in blood platelets that can result in internal bleeding*.

So far, more than 260 patients have filed a Pradaxa lawsuit alleging internal bleeding, resulting in the consolidation of cases to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with their doctor or a lawyer about their legal options. However, due to the specialized nature of federal drug cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Boehringer Ingelheim, 4/30/13; us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/04-30-13-boehringer-ingelheim-pharmaceuticals-prescribing-information-pradaxa-dabigatran-etexilate-mesylate.html

**FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm

***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf

****New England Journal of Medicine, 4/4/13; nejm.org/doi/full/10.1056/NEJMp1302834

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-lawsuits/side-effects-settlements/prweb10715463.htm


Source: prweb



comments powered by Disqus